Attorney Docket No. PU60560

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/US2004/034944 21 October 2004 22 October 2003

TITLE OF INVENTION

2-(3,4-DIMETHYLPHENYL)-4-{[2-HYDROXY-3'(1H-TETRAZOL-5-YL)BIPHENYL-3-YLIHYDRAZONO}-5-METHYL-2,4-DIHYDRPYROZOL-3-ONE CHOLINE

APPLICANT(S) FOR DO/US Christopher S. BROOK, Li-Jen J. PING

FILING OF AN INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97.

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. These documents were also cited in copending U.S. Application Serial No. 10/296,688 filed July 3, 2003. Copies of the cited references are not enclosed herewith but are available in the filewrapper of U.S. Application Serial No. 10/298,688. Applicants request that the Examiner transfer these references from the above-referenced application for use herein. If the Examiner prefers and upon request, Applicants will provide a separate and complete set of said references (120 in all).

This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Wayne J. Dustman Attorney for Applicants Registration No. 33,870

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5023 Fax (610) 270-5090 N:\WJD\TPO\PU60560\NATIONAL STAGE.doc

is the constant of the constan

Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office ATTY. DOCKET NO. PU60560

Sheet 1 of 2 . linternational Application No. PCT/US2004/034944

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT Stephen Moore

FILING DATE GROUP
Herewith Not Assigned

U.S. PATENT DOCUMENTS

Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
 851,444	4/1907	Shulthess			
4,435,417	03/06/84	Toja, et al.			
4,510,149	04/09/85	Cozzi, et al.			
4,880,788	11/14/89	Moake, et al.			
5,482,546	01/09/96	Eida, et al.			
6,214,813	04/10/01	Zhang, et al.			
5,746,821	5-May-98	Hays			
5,760,038	2-Jun-98	Murugesan, et al.			
6,238,442	29-May-01	Schumacher, et al			
6,248,871	19-Jun-01	Ebenezer, et al			
6,436,915	20-Aug-02	Zhang, et al.			
6,280,959	08/28/2001	Gleason, et al			
5,532,202	07/02/1996	Yoshida			
6,238,442	05/29/2001	Schumacher, et al.			
5,622,818	04/22/1997	Kapp, et al.			
5,669,967	09/23/1997	Hays			
3,366,619	01/30/1968	DeLucia			
2,950,273	08/23/1960	Pelz			
4,948,900	08/14/1990	Iijima et al.			
5,932,546	08/03/99	Barrett et al.			
US04/0082626	Pub04/29/04	Takemoto et al.			
US04/0063764	Pub04/01/04	Takemoto et al.			
US03/0060453	Pub03/27/03	Zhang, et al.			
5,326,776	07/05/1994	Winn, et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass		lation
DE 100.050	12/1007	1.054			Yes	No
 DE 193,350	12/1907	AGFA				
779 880	24.07.57	GB				
 WO 98/46606	22.10.98	PCT				
 1 207 155	24.07.00	EP				
 1 104 674	06.06.01	EP				
1 253 142	23.01.01	EP				

WO 01/77080	26.01.01	WIPO	
WO 02/059099	25.01.02	WIPO	
WO 02/059100	25.01.02	WIPO	
WO 00/35446	22.06.2000	WIPO	
WO 01/07423	01.02.2001	WIPO	
WO 01/21180	29.03.2001	WIPO	
WO 01/17349	15.03.2001	WIPO	
WO 93/17681	16-Sep-93	WIPO	
WO 02/057300	25-Jul-02	WIPO	
WO03/074550	12-Sep-03	WIPO	
WO03/098992	4-Dec-03	WIPO	
826,207	07/23/1956	GB	
*0 638 617	04.08.1994	EP	X
WO 99/15500	01.04.1999	WIPO	
WO 99/11262	11.03.1999	WIPO	
WO 01/34585	05/17/01	WIPO	
WO 02/49413	06/27/02	WIPO	
WO 02/085343	10/31/02	WIPO	
WO 03/103686	12/18/03	WIPO	
WO 04/054515	07/01/04	WIPO	
WO 96/40750	12/19/96	WIPO	
DE 193350	11/03/1904	AGFA	X
EP - 1 104 674	06/08/01	EP	X
**2002-371213	26.12.2002	JP	X
WO 05/041867	12.05.2005	WIPO	
WO 04/096154	11.11.2004	WIPO	
WO 94/26709	24.11.1994	WIPO	
WO 03/045379	05.06.03	WIPO	
WO 01/89457	29.11.2001	WIPO	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Yamazaki, et al., Database HCAPLUS, AN 1995: Abstract, 196968.			
	A. Esteve, Ann. Pharm. Franc., 1950, Vol. 8, No. 9-10, pp. 594-604.			
	Morris, et al., Anti-Cancer Drugs, 1997, Vol. 8, No. 8, pp. 746-755.			
	Duffy, et al., J. Med. Chem., 2001, Vol. 44, No. 22, Abstract No. XP002197261.			
	Bartley, et al., Cell, 1994, Vol. 77, pp. 1117-1124.			
	Olszewski, et al., Database CAPLUS on STN, 1995, Chem. Abstracts, No.122:81695.			
-	Olszewski, et al., J. Org. Chem., 1994, Vol. 59, pp. 4285-4296.			
	Lamb, et al., Nucleic Acids Research, 1995, Vol. 23, No. 16, pp. 3283-3289			
	Seidel, et al., Proc. Natl. Acad. Sci. USA, March 1995, Vol. 92, pp. 3041-3045			

Berkhout, et al., J. of Biological Chemistry, June, 1997, Vol. 272, No. 26, pp. 16404-16413.
Vermeulen, et al., Blood, 1998, Vol. 92, No. 3, pp. 894-900
Hasegawa, et al., Int. J. Immunopharmac, 1996, Vol. 18, No. 2, pp. 103-112
Kumamoto, et al., British Journal of Haematology, 1999, Vol. 105, pp. 1025-1033
Shiotsu, et al., Experimental Hematology, 1998, Vol. 26, pp. 1195-1201
Komatsu, et al., Blood, 1996, Vol. 87, No. 11, pp. 4552-4560
Uguccioni, et al., J. Exp. Med., 1996, Vol. 183, pp. 2397-2384
Taylor, et al., J. Org. Chem., 1987, Vol. 52, pp. 4107-4110
Kuter, et al., Seminars in Hematology, April 2000, Vol. 37, No. 2, pp. 41-49
Ballestrero, et al., Oncology, 2000, Vol. 59, pp. 7-13
Sawai, et al., Journal of Leukocyte Biology, July 2000, Vol. 68, pp. 137-143
Vigon, et al., Proc. Natl. Acad. Sci. USA, June 1992, Vol. 89, pp. 5640-5644
Laurenz, et al., Comp. Biochem Physiol., 1997, Vol. 116A, No. 4, pp. 369-377
Metcalf, et al., Nature, June 16, 1994, Vol. 369, pp. 519-520
Bussel, et al., Seminars in Hematology, 2000, Vol. 37, pp. 1-49 (Table of Contents)
McDonald, et al., Am. J. of Pediatric Hematology/Oncology, 1992, Vol. 14, No. 1, pp. 8-21
Souyri, et al., Cell, 1990, Vol. 63, pp. 1137-1147
Bazan, et al., Pro. Natl. Acad. Sci. USA, September 1990, Vol. 87, pp. 6934-6938
Sauvage, et al., Nature, June 16, 1994, Vol. 369, pp. 533-538
Wendling, et al., Nature, June 16, 1994, Vol. 369, pp.571-574
Kaushansky, et al., Nature, June 16, 1994, Vol. 369, pp. 568-571
Bartley, et al., Cell, 1994, Vol. 77, pp. 1117-1124
King, et al., The Journal of Immunology, 2000, pp. 3774-3782
Kikuta, et al., Experimental Hematology, 2000, Vol. 28, pp. 311-317
Somlo, et al., Blood, May 1, 1992, Vol. 93, No. 9, pp. 2798-2806
Kirley-Neumann, et al., Cytokines, Cellular & Molecular Therapy, 2000, Vol. 6, pp. 47-56
Egger, et al., Bone Marrow Transplant, 1998, Vol. 22, pp. 34-35
Gaudron, et al., Stem Cells, 1999, Vol. 17, pp. 100-106
Fetscher, et al., Current Opinion in Hematology, 2000, Vol. 7, pp. 255-260
Clemons, et al., Breast Cancer Res. Treatment, 1999, Vol. 57, pp. 127
Greene, "Protective Groups in Organic Synthesis", 1981, Table of Contents.
Methia, et al., Blood, 1993, Vol. 82, No. 5, pp. 1395-1401
*Yamazaki, et al., Japn. J. Toxicol. Environ. Health, 1994, Vol. 94, No. 5, pp. 448-453.
Duffin, et al., J. of the Chem. Soc., 1954, pp. 408-41.
King, et al., Scand. J. of Immunol., 1999, vol. 49, no. 2, pp. 184-192.
Konica Corp. Derwent No. 92-077508/10, 1992.
Mitsubishi Pharma Corp. Derwent No. 2003-845201/78, 2003.
Mitsubishi Pharma Corp. Derwent No. 2003-767492/72, 2003.
*Balli, et al., Dyes. Pigm., 1981, Vol. 2, No. 2, pp. 93-124

10/576411

		:DUC	
	*Balli, et al., Justus Liebigs Ann. Ch	em., 1966, Vol. 699, pp. 133-134.	
	Dziomko, et al., Chem. Heterocycl. Compd., 1984, Vol. 20, No. 2, pp. 196-200.		
	Duffy, et al., J. Med. Chem., 2001, Vol. 44, No. 22, p. 3730-3745.		
	Kimura, et al., FEBS Letters, 1998, Vol. 428, No. 3, pp. 250-254.		
	*Beckert, et al., Monatshefte Fur Chemie, 1989, Vol. 120, pp. 1125-1137.		
	*A. Esteve, Ann. Pharm. Franc., 195	50, Vol. 8, No. 9-10	
	PCT/US2004/13468 filed April 29, 2	004 - Attorney Docket No. PU60236. (WO 04/096154)	
	PCT/US2004/034944 filed Oct. 21, 2	2004 -Attorney Docket No. PU60560. (WO 05/041867)	
	**Minssen-Guette, et al., Bulletin De La	Societe Chimique De France, 1986, No. 5, pp. 2106-2110.	
	European Search report dated Decemb	er 15, 2003.	
	European office action dated February 2, 2005. Bussel, et al., Seminars in Hematology, 2000, Vol. 37, pp. 1-49 (whole journal). see ids #7 Balli, et al., Dyes. Pigm., 1981, Vol. 2, No. 2, pp. 93-124 (sent original)		
1	Balli, et al., Justus Liebigs Ann. Chem., 1966, Vol. 699, pp. 133-144. (sent original)		
	** ORIGINAL & TRANSLATION		
	*TRANSLATION ONLY		
•	DATE CONSIDERED		
·EXAMI	NER: Initial if citation considered whether	or not citation is in conformance with MPEP 609: Draw	

·EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.
n:\wjd\tpo\p51352\complete ids cited in p51141 transfer to p51352.doc